Meeting
2015 ASCO Annual Meeting
Interpreting the febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis.
Authors
Judy Truong
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Judy Truong , Esther Lee , Maureen E. Trudeau , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Symptom Management/Supportive Care
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9626)
DOI
10.1200/jco.2015.33.15_suppl.9626
Abstract #
9626
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).
First Author: Douglas W. Blayney
Poster
2019 ASCO Annual Meeting
Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.
First Author: Daniele Rossini
Poster
2016 ASCO Quality Care Symposium
Prophylactic use of Granulocyte-colony stimulating factors (G-CSF) in cancer patients: Adherence to NCCN guidelines.
First Author: Rashi Khanna
Poster
2013 ASCO Annual Meeting
A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer.
First Author: Roopa Lakhanpal